Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRTX-1001 in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT05135091Phase 3Recruiting
- Sponsor
- Neurona Therapeutics
- Start
- Jun 2022
- Primary completion
- Feb 2029
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NRTX-1001 in mesial temporal lobe epilepsy (MTLE) (3 arms), sponsored by Neurona Therapeutics. Primary endpoints: Frequency of serious or severe adverse events at 1 year and Change in disabling seizure frequency. Started Jun 2022; status: recruiting.
02
Drugs
NRTX-1001
03
Conditions
mesial temporal lobe epilepsy (MTLE)
Beyond the preview
Go deeper on NCT05135091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135091.